HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Syros Pharmaceuticals (NASDAQ:SYRS) and maintained a $15 price target.
August 09, 2023 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syros Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $15.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Syros Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100